Literature DB >> 30169874

Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease.

Cédric Villain1,2, Marie Metzger2, Christian Combe3,4, Denis Fouque5, Luc Frimat6,7, Christian Jacquelinet2,8, Maurice Laville5, Serge Briançon7, Julie Klein9,10, Joost P Schanstra9,10, Bruce M Robinson11, Nicolas Mansencal2,12, Bénédicte Stengel2, Ziad A Massy1,2.   

Abstract

BACKGROUND: Although chronic kidney disease (CKD) and age are major risk factors for cardiovascular disease (CVD), little is known about the relative proportions of atheromatous and non-atheromatous CVD by age in CKD patients.
METHODS: We used baseline data from the French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort of 3033 patients (65% men) with CKD Stages 3-4 to study crude and adjusted associations between age, the estimated glomerular filtration rate (eGFR), atheromatous CVD (coronary artery disease, peripheral artery disease and stroke) and non-atheromatous CVD (heart failure, cardiac arrhythmia and valvular heart disease).
RESULTS: Mean age was 66.8 and mean Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR was 32.9 mL/min/1.73 m2. In the <65, (65-74), (75-84) and ≥85 year age groups, the prevalence was, respectively, 18.7, 35.5, 42.9 and 37.8% for atheromatous CVD, and 14.9, 28.4, 38.1 and 56.4% for non-atheromatous CVD. After adjusting for albuminuria, sex and CVD risk factors, the odds ratio (OR) [95% confidence interval (CI)] for (65-74), (75-84) and ≥85 age groups (compared with the <65 group) was, respectively, 1.99 (1.61-2.46), 2.89 (2.30-3.62), 2.72 (1.77-4.18) for atheromatous CVD and 2.07 (1.66-2.58), 3.15 (2.50-3.97), 7.04 (4.67-10.61) for non-atheromatous CVD. Compared with patients with an eGFR ≥30 mL/min/1.73 m2, those with an eGFR <30 mL/min/1.73 m2 had a higher OR for atheromatous CVD [1.21 (1.01-1.44)] and non-atheromatous CVD [1.16 (0.97-1.38)].
CONCLUSIONS: In this large cohort of CKD patients, both atheromatous and non-atheromatous CVD were highly prevalent and more frequent in older patients. In a given age group, the prevalence of atheromatous and non-atheromatous CVD was similar (except for a greater prevalence of non-atheromatous CVD after 85).
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; chronic kidney disease; elderly; epidemiology; risk factors

Year:  2020        PMID: 30169874     DOI: 10.1093/ndt/gfy277

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  9 in total

Review 1.  Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

Authors:  Carolla El Chamieh; Sophie Liabeuf; Ziad Massy
Journal:  Toxins (Basel)       Date:  2022-04-14       Impact factor: 5.075

Review 2.  Valvular Heart Disease in Patients with Chronic Kidney Disease.

Authors:  Konstantina Kipourou; Jamie M O'Driscoll; Rajan Sharma
Journal:  Eur Cardiol       Date:  2022-01-31

3.  Zebrafish Model-Based Assessment of Indoxyl Sulfate-Induced Oxidative Stress and Its Impact on Renal and Cardiac Development.

Authors:  Paul Wei-Hua Tang; Ping-Hsun Wu; Yi-Ting Lin; Chen-Hao Chiu; Tien-Li Cheng; Wen-Hui Guan; Hugo You-Hsien Lin; Kun-Tai Lee; Yau-Hung Chen; Chien-Chih Chiu; Wangta Liu
Journal:  Antioxidants (Basel)       Date:  2022-02-16

4.  Ageing meets kidney disease.

Authors:  Alberto Ortiz; Francesco Mattace-Raso; María José Soler; Denis Fouque
Journal:  Clin Kidney J       Date:  2022-06-30

Review 5.  Indoxyl Sulfate, a Uremic Endotheliotoxin.

Authors:  Guillaume Lano; Stéphane Burtey; Marion Sallée
Journal:  Toxins (Basel)       Date:  2020-04-05       Impact factor: 4.546

6.  Female AhR Knockout Mice Develop a Minor Renal Insufficiency in an Adenine-Diet Model of Chronic Kidney Disease.

Authors:  Camélia Makhloufi; Fanny Nicolas; Nathalie McKay; Samantha Fernandez; Guillaume Hache; Philippe Garrigue; Philippe Brunet; Benjamin Guillet; Stéphane Burtey; Stéphane Poitevin
Journal:  Int J Mol Sci       Date:  2020-04-03       Impact factor: 5.923

7.  Impact of age on cardiovascular drug use in patients with chronic kidney disease.

Authors:  Cédric Villain; Sophie Liabeuf; Marie Metzger; Christian Combe; Denis Fouque; Luc Frimat; Christian Jacquelinet; Maurice Laville; Serge Briançon; Ronald L Pisoni; Nicolas Mansencal; Bénédicte Stengel; Ziad A Massy
Journal:  Clin Kidney J       Date:  2019-06-10

8.  Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD.

Authors:  Ziad A Massy; Jean Ferrières; Eric Bruckert; Céline Lange; Sophie Liabeuf; Maja Velkovski-Rouyer; Bénédicte Stengel
Journal:  Kidney Int Rep       Date:  2019-07-30

9.  Consequences of oral antithrombotic use in patients with chronic kidney disease.

Authors:  Solène M Laville; Oriane Lambert; Aghiles Hamroun; Marie Metzger; Christian Jacquelinet; Maurice Laville; Luc Frimat; Denis Fouque; Christian Combe; Carole Ayav; Roberto Pecoits-Filho; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Clin Transl Sci       Date:  2021-06-24       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.